>Dr. Dieterich said that he thought the recently-reported in-vitro ( replicon system ) results showing a negative interaction between riba and NM-283 would not carry over into in-vivo studies. I'd be more inclined to trust him on this if not for some of the other questionable statements he made.<
That was exactly my reaction. During the webcast, I was waiting for someone other than Dieterich to second this prediction, but no one did. That’s why I did not include Dieterich’s prediction in my webcast summary.
Perhaps I missed something, but why wouldn't the FDA request both VRTX and IDIX use the same metrics - assay cutoffs in their studies. If I read correctly, VRTX results are based on a cutoff of 10 IU, while IDIX results are at a cutoff of 20 IU. This to me seems very significant.
Market Data 
Markets 
AI
